Current state and next-generation CAR-T cells in multiple myeloma

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor T cells (CAR-T cells) represent a significant advancement in treating blood cancers.
• Ide-cel, a BCMA-targeting CAR-T therapy, is now approved for multiple myeloma (MM).

Purpose of the Study:

• To review clinical trials of CAR-T cells in multiple myeloma.
• To discuss CAR-T cell resistance mechanisms.
• To explore next-generation CAR-T cell research.

Main Methods:

• Review of clinical trials involving BCMA-directed CAR-T cells (ide-cel, cilta-cel, orva-cel, CT053, P-BCMA-101, bb21217, GC012F, ALLO-715).
• Analysis of documented CAR-T cell resistance mechanisms.
• Survey of emerging CAR-T cell technologies.

Main Results:

• Multiple BCMA-targeting CAR-T therapies are in advanced clinical development for multiple myeloma.
• Key resistance mechanisms include antigen loss, immune suppression, and CAR-T cell exhaustion.
• Next-generation CAR-T cells incorporate advanced designs like armored, gated, or commuting CARs, gene editing, and alternative cell types (γδT, NK cells).

Conclusions:

• CAR-T cell therapy is a transformative approach for multiple myeloma, with ongoing research addressing resistance.
• Future CAR-T cell generations aim to overcome current limitations and expand therapeutic potential.